CCCZ Guesttalk – Targeted treatment of Morbus Waldenström in 2022 and beyond

Dr. Steven Treon, Dana Farber Cancer Institute, Boston, USA


Kleiner Hörsaal Path C22
University Hospital Zurich
8091 Zürich




4.30 - 5.30 pm

Steve Treon is the Director of the Bing Center for Waldenstrom’s Macroglobulinemia (WM) at the Dana Farber Cancer Institute (DFCI), a Professor of Medicine at Harvard Medical School, and Chair of the WM Clinical Trials Group. His laboratory first identified highly recurring activating mutations in MYD88 and CXCR4 using whole genome sequencing and also identified that Bruton’s tyrosine kinase (BTK) was a downstream target of mutated MYD88, and enabled a clinical trial with the BTK inhibitor ibrutinib that resulted in the first-ever approval of a drug by the U.S. FDA and the European Medicines Agency for WM. Professor Treon also made major contributions to the investigation and advancement of many novel agents used to treat WM including monoclonal antibodies, nucleoside analogues, bendamustine, proteasome inhibitors, and BTK inhibitors.

He has published extensively on topics in WM and myeloma with over 250 peer-reviewed original reports, authoritative reviews, editorials, and chapters included in high-impact journals and textbooks and has been the principal organizer of the International Workshops on WM since 2002.


Verantwortlicher Fachbereich

This site is registered on as a development site. Switch to a production site key to remove this banner.